Welcome to our dedicated page for Siga Technologie news (Ticker: SIGA), a resource for investors and traders seeking the latest updates and insights on Siga Technologie stock.
SIGA Technologies, Inc. (SIGA) is a commercial-stage pharmaceutical company whose news flow centers on its role in health security and orthopoxvirus antivirals. The company regularly issues press releases on its financial results, government contracts, regulatory milestones, and corporate developments, giving investors and observers insight into the performance and direction of the business.
A recurring theme in SIGA’s news is the commercial progress of its flagship antiviral medicine, TPOXX (tecovirimat). Company updates describe product revenues from oral and IV TPOXX, including deliveries to the U.S. Strategic National Stockpile and sales to the U.S. Department of Defense and international customers. Releases also discuss procurement orders, outstanding orders, and the mix of domestic and international product sales.
Regulatory and development milestones are another key news category. SIGA has reported authorizations and approvals of TPOXX in multiple jurisdictions, including approval in Japan under the name TEPOXX for orthopoxvirus-related indications. The company also announces modifications to its BARDA 19C contract that add funding for pediatric development and manufacturing activities, reflecting ongoing development work around TPOXX.
Quarterly and annual earnings releases provide detailed financial statements, highlighting product sales, total revenues, operating income or loss, and net income or loss. These updates often include commentary from management on business performance, health security priorities, and the status of government and international contracts.
In addition, SIGA’s news includes governance and capital allocation items, such as the declaration of special cash dividends and appointments to the board of directors. Together, these disclosures offer a view into SIGA’s financial results, strategic relationships with governments and public health agencies, and its continuing focus on TPOXX as a countermeasure against orthopoxvirus-related diseases.
SIGA Technologies (SIGA) announced a potential contract with the Public Health Agency of Canada (PHAC) for up to 33,300 courses of oral TPOXX (tecovirimat) over five years. The contract includes delivery of 18,500 courses by March 31, 2023, with an optional 14,800 courses afterward. This follows a prior contract from the Department of National Defence for 15,325 courses. SIGA plans to submit a marketing authorization application to Health Canada by the end of 2020, aiming for approval in 2021.
SIGA Technologies, a pharmaceutical company focused on health security, announced that CEO Dr. Phillip L. Gomez will participate in a fireside chat at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020, at 8:00 a.m. ET. The event will be accessible via a live webcast on the company's website, with a replay available afterward. SIGA’s primary product is TPOXX® (tecovirimat), an antiviral approved for smallpox treatment. The U.S. maintains a stockpile of 1.7 million doses under Project BioShield.
In Q2 2020, SIGA Technologies reported total revenues of $40.3 million, a significant increase from $28.8 million in Q2 2019. Operating income improved to $3.9 million compared to a loss of $1.7 million a year earlier. The company successfully delivered 117,000 courses of TPOXX to the Strategic National Stockpile, generating $36.2 million in revenue. SIGA also expanded its international presence with a delivery of 2,500 courses to Canada. The company filed a Marketing Authorisation Application for oral tecovirimat, targeting approval in H2 2021.
SIGA Technologies, Inc. (SIGA) will host a webcast and conference call on August 6, 2020, at 4:30 P.M. ET to discuss a business update. Dr. Phil Gomez, CEO, and Daniel Luckshire, CFO, will participate. The call will be available on the company's website or by telephone. A replay will be provided for two weeks. SIGA focuses on health security, with TPOXX® as their lead product, approved for smallpox treatment. The company signed a contract with BARDA worth $51.6M for additional TPOXX development.
SIGA Technologies has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for oral tecovirimat, previously approved as TPOXX by the FDA. This filing seeks a broader indication to treat smallpox, monkeypox, cowpox, and Vaccinia complications, targeting approval in the second half of 2021. SIGA aims to enhance access to this essential antiviral across Europe, following its collaborative development with the U.S. Government. The U.S. maintains a stockpile of 1.7 million doses of TPOXX to mitigate bioterror threats.
SIGA Technologies (NASDAQ: SIGA) announced the delivery of oral TPOXX® (tecovirimat) to the U.S. Department of Health and Human Services (HHS), valued at approximately $32 million. This delivery marks the initial phase of a contract option worth $101.3 million under the 2018 BARDA Contract. The contract has up to $414 million remaining for future procurement. Dr. Phil Gomez emphasized the importance of preparing for potential biological threats during the ongoing COVID-19 pandemic.
SIGA Technologies, Inc. (SIGA) has received an increase in funding of approximately $23 million from the United States Department of Defense (DoD) to support research for expanding the FDA label of its antiviral drug TPOXX (tecovirimat) for Post-Exposure Prophylaxis (PEP) against smallpox. This potential label expansion is crucial in the event of a smallpox outbreak, as vaccines alone have limitations in effectiveness. TPOXX may be administered over 28 days for PEP, contrasting with the 14-day treatment for active infections. The company aims to enhance early treatment options for individuals at risk.
On June 1, 2020, SIGA Technologies, Inc. (SIGA) announced that its 2020 Annual Meeting of Stockholders will be held virtually on June 16, 2020, at 10:30 a.m. Eastern Time, due to COVID-19 safety concerns. Stockholders as of April 24, 2020, can attend the meeting via a live audio webcast. They must submit their votes in advance, as voting during the meeting will not be permitted. SIGA focuses on health security and is known for TPOXX, a treatment for smallpox. A notice regarding the virtual format has been filed with the SEC.
SIGA Technologies announced the delivery of 2,500 courses of TPOXX® (tecovirimat) to the Canadian Department of National Defence as part of an agreement for up to 15,325 courses valued at $14.3 million. Deliveries are expected to continue pending regulatory approval by Health Canada. Additionally, SIGA plans to deliver $101.3 million of TPOXX to the U.S. Government related to a BARDA contract. The contract could yield up to $414 million in future purchases, underscoring SIGA's role in biodefense and health security.
FAQ
What is the current stock price of Siga Technologie (SIGA)?
What is the market cap of Siga Technologie (SIGA)?
